Metabolix (NASDAQ: YTEN) is one of 214 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Metabolix to related businesses based on the strength of its profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Metabolix and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Metabolix 0 0 0 0 N/A
Metabolix Competitors 490 2383 6476 122 2.66

As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.60%. Given Metabolix’s rivals higher probable upside, analysts plainly believe Metabolix has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Metabolix and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Metabolix $1.16 million -$7.60 million -2.61
Metabolix Competitors $220.75 million -$39.68 million -59.61

Metabolix’s rivals have higher revenue, but lower earnings than Metabolix. Metabolix is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Metabolix has a beta of 3.54, meaning that its stock price is 254% more volatile than the S&P 500. Comparatively, Metabolix’s rivals have a beta of 1.53, meaning that their average stock price is 53% more volatile than the S&P 500.

Profitability

This table compares Metabolix and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Metabolix -190.57% -145.04% -81.21%
Metabolix Competitors -3,958.84% -119.46% -44.25%

Insider and Institutional Ownership

9.2% of Metabolix shares are owned by institutional investors. Comparatively, 46.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 11.2% of Metabolix shares are owned by company insiders. Comparatively, 13.9% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Metabolix rivals beat Metabolix on 6 of the 9 factors compared.

Metabolix Company Profile

Yield10 Bioscience, Inc., formerly Metabolix, Inc., is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The Company concentrates on technologies that enables it to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter. The Company has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.

Receive News & Ratings for Metabolix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metabolix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.